title: Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin II and aldosterone in patients with chronic congestive heart failure.
abstract: In an open trial 5 mg ramipril daily for 2 weeks was administered to 11 patients with congestive heart failure. 24-hour plasma profiles of atrial natriuretic peptide (ANP), antidiuretic hormone (ADH), angiotensin II (Ang II) and aldosterone (Aldo) were determined before and on days 1 and 15 of ramipril treatment, respectively. Urinary sodium excretion was also measured at the same time points. There were no relevant differences in the 24-hour profiles of ANP and ADH. Ang II values dropped as expected on the first day of ramipril treatment from 11.2 pg/ml to 2.9 pg/ml at 3 h post administration and from 6.7 pg/ml (predose) to 1.8 pg/ml at 2 h post administration on day 15. Plasma aldosterone values increased slightly from day 1 to day 15, sodium excretion increased from 125.9 mmol to 166.5 mmol/24 h; however, both changes in the 24-hour profiles were nonsignificant. A clinically relevant improvement in the severity of CHF was observed. From a total of 121 reported symptoms according to McKee et al., 35 showed an improvement; 81 remained unchanged, in only 5 symptoms a deterioration was observed. According to the NYHA-classification 5 patients improved from grade III to II, 6 remained unchanged.
  
  
  CONCLUSIONS
  ACE inhibition does not induce changes in ANP or ADH levels in the resting state while Ang II decreases. A slight increase in aldosterone levels may be due to increased sodium excretion.
authors.affiliation: 2nd Medical Clinic, Technical University of Aachen, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Heintz
authors.forename: M
authors.initials: M
authors.lastname: Verho
authors.forename: D
authors.initials: D
authors.lastname: Brockmeier
authors.forename: R
authors.initials: R
authors.lastname: Kirsten
authors.forename: K
authors.initials: K
authors.lastname: Nelson
authors.forename: B
authors.initials: B
authors.lastname: Rangoonwala
authors.forename: S
authors.initials: S
authors.lastname: Maigatter
authors.forename: G
authors.initials: G
authors.lastname: Lückel
authors.forename: H
authors.initials: H
authors.lastname: Kierdorf
authors.forename: H G
authors.initials: HG
authors.lastname: Sieberth
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000450:Aldosterone / Q000097:blood*; D000804:Angiotensin II / Q000097:blood*; D009320:Atrial Natriuretic Factor / Q000097:blood*; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D017257:Ramipril / Q000494:pharmacology* / Q000627:therapeutic use; D012964:Sodium / Q000652:urine; D014667:Vasopressins / Q000097:blood*
chemical_list: D014667:Vasopressins; D000804:Angiotensin II; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D012964:Sodium; D017257:Ramipril